- Home
- CANG vs ATYR Comparison
CANG vs ATYR Comparison
Compare CANG & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- ATYR
- Stock Information
- Founded
- CANG 2010
- ATYR 2005
- Country
- CANG China
- ATYR United States
- Employees
- CANG N/A
- ATYR N/A
- Industry
- CANG Computer Software: Prepackaged Software
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CANG Technology
- ATYR Health Care
- Exchange
- CANG Nasdaq
- ATYR Nasdaq
- Market Cap
- CANG 544.1M
- ATYR 451.3M
- IPO Year
- CANG 2018
- ATYR 2015
- Fundamental
- Price
- CANG $4.82
- ATYR $4.72
- Analyst Decision
- CANG Strong Buy
- ATYR Strong Buy
- Analyst Count
- CANG 1
- ATYR 6
- Target Price
- CANG $8.00
- ATYR $20.20
- AVG Volume (30 Days)
- CANG 823.4K
- ATYR 5.9M
- Earning Date
- CANG 08-28-2025
- ATYR 08-12-2025
- Dividend Yield
- CANG N/A
- ATYR N/A
- EPS Growth
- CANG N/A
- ATYR N/A
- EPS
- CANG 0.00
- ATYR N/A
- Revenue
- CANG $247,219,627.00
- ATYR N/A
- Revenue This Year
- CANG $431.64
- ATYR $551.06
- Revenue Next Year
- CANG $23.36
- ATYR $1,874.58
- P/E Ratio
- CANG $2,589.59
- ATYR N/A
- Revenue Growth
- CANG 46.60
- ATYR N/A
- 52 Week Low
- CANG $1.40
- ATYR $1.67
- 52 Week High
- CANG $9.66
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- CANG 45.45
- ATYR 42.73
- Support Level
- CANG $4.73
- ATYR $5.46
- Resistance Level
- CANG $5.14
- ATYR $7.29
- Average True Range (ATR)
- CANG 0.27
- ATYR 0.65
- MACD
- CANG -0.07
- ATYR -0.13
- Stochastic Oscillator
- CANG 8.33
- ATYR 2.66
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and related businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives majority of its revenue from the bitcoin mining business.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.